(Q40142949)

17 September 2017

1 reference

reason for preferred rank

title

Ceftriaxone A Review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use (English)

1 reference

10.2165/00003495-198427060-00001

https://api.crossref.org/works/10.2165/00003495-198427060-00001

30 September 2023

Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6329638

30 September 2023

3

R N Brogden

1 reference

17 September 2017

D. M. Richards

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6329638

30 September 2023

R. C. Heel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6329638

30 September 2023

T. M. Speight

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6329638

30 September 2023

G. S. Avery

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6329638

30 September 2023

language of work or name

1 reference

1 June 1984

1 reference

17 September 2017

1 reference

17 September 2017

volume

27

1 reference

17 September 2017

issue

6

1 reference

17 September 2017

page(s)

469-527

1 reference

Pseudomonas aeruginosa and Acinetobacter calcoaceticus: in vitro susceptibility of 150 clinical isolates to five beta-lactam antibiotics and tobramycin

17 September 2017

cites work

1 reference

12 December 2020

Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.

1 reference

12 December 2020

Relative substrate affinity index values: a method for identification of beta-lactamase enzymes and prediction of successful beta-lactam therapy

1 reference

12 December 2020

Comparative Non-Blind Trial of Ceftriaxone and Gentamicin in the Treatment of Complicated Urinary Tract Infections

1 reference

12 December 2020

A comparative trial of ceftriaxone and a penicillin/chloramphenicol combination in gynaecological infections complicated by peritonitis

1 reference

12 December 2020

Comparative in vitro activity of 8 cephalosporins on 109 strains of Neisseria gonorrhoeae and 60 strains of Neisseria meningitidis.

1 reference

12 December 2020

Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin

1 reference

12 December 2020

Susceptibility of 324 Nonfermentative Gram-Negative Rods to 6 Cephalosporins and Azthreonam

1 reference

12 December 2020

Antibiotic prevention in hysterectomy. Effectivity of a single preoperative ceftriaxon dose

1 reference

12 December 2020

Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis

1 reference

12 December 2020

Ceftriaxone for the Treatment of Serious Infections

1 reference

12 December 2020

Simultaneous simulation of the serum profiles of two antibiotics and analysis of the combined effect against a culture of Pseudomonas aeruginosa

1 reference

12 December 2020

Treatment of septic burns with a third-generation cephalosporin (cefatriaxon)

1 reference

12 December 2020

Efficacy of ceftriaxone and gentamicin in an abscess model

1 reference

12 December 2020

Dose-ranging study of ceftriaxone for uncomplicated gonorrhea in men.

1 reference

12 December 2020

In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.

1 reference

12 December 2020

Ceftriaxone (Ro 13-9904) therapy of serious infection

1 reference

12 December 2020

Clinical and bacteriological results in urinary tract infections with single-dose Ro 13-9904 (Rocephin).

1 reference

12 December 2020

Comparison of ceftriaxone and traditional therapy of bacterial meningitis

1 reference

12 December 2020

Activities of eight new beta-lactam antibiotics and seven antibiotic combinations against Neisseria meningitidis

1 reference

12 December 2020

Comparison of ceftriaxone with standard therapy for bacterial meningitis

1 reference

12 December 2020

Comparative antipseudomonal activity of some newer beta-lactam agents

1 reference

12 December 2020

Combination effect of ceftriaxone with four aminoglycosides on nonfermenting gram-negative bacteria

1 reference

12 December 2020

The effect of n-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans

1 reference

12 December 2020

Ceftriaxone therapy of serious bacterial infections

1 reference

12 December 2020

Single-dose pharmacokinetics of ceftriaxone in infants and young children

1 reference

12 December 2020

Susceptibilities of gentamicin-resistant Gram-negative aerobic bacilli to cefotetan and other beta-lactams.

1 reference

12 December 2020

Clinical Pharmacology of Ceftriaxone in Patients with Neoplastic Disease

1 reference

12 December 2020

Comparative study of ceftriaxone and aqueous procaine penicillin G in the treatment of uncomplicated gonorrhea in women

1 reference

12 December 2020

Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae

1 reference

12 December 2020

Effect of 3-substitution in oxyiminocephalosporins on the stability to and the inhibition of various beta-lactamases

1 reference

12 December 2020

Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli

1 reference

12 December 2020

Third-Generation and Investigational Cephalosporins: II. Microbiologic Review and Clinical Summaries

1 reference

12 December 2020

Treatment of severe lower respiratory tract infections with ceftriaxone (Ro 13-9904). A pilot study

1 reference

12 December 2020

Comparison of the in-vitro activity of Sch 29482 with thirteen other beta-lactam antibiotics against Neisseria meningitidis and Neisseria gonorrhoeae (including penicillinase-producing isolates)

1 reference

12 December 2020

Effect of Broad-Spectrum Cephalosporins on the Microbial Flora of Recipients

1 reference

12 December 2020

Ceftriaxone levels in blood and tissue during cardiopulmonary bypass surgery

1 reference

12 December 2020

Treatment of Experimental Ascending <i>Escherichia coli</i> Pyelonephritis with Ceftriaxone Alone and in Combination with Gentamicin

1 reference

12 December 2020

Absolute Bioavailability of Ceftriaxone after Intramuscular Administration to Healthy Volunteers

1 reference

12 December 2020

Pharmacokinetics of Ceftriaxone in Pediatric Patients With Meningitis

1 reference

12 December 2020

[Bacteriological, pharmacological and clinical comparison between amoxycillin and ceftriaxone in the treatment of 300 purulent meningitis ]

1 reference

12 December 2020

Ceftriaxone - a new broad-spectrum semisynthetic cephalosporin. In vitro activity against gram-negative bacilli sensitive and resistant to gentamicin.

1 reference

12 December 2020

Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents

1 reference

12 December 2020

Antibacterial activity of Ro 13-9904 and preliminary experience in gonorrhoea and chronic urinary tract infections

1 reference

12 December 2020

Hypoprothrombobinaemic bleeding associated with ceftriaxone

1 reference

12 December 2020

Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis

1 reference

12 December 2020

Comparison of Susceptibilities of Anaerobic Bacteria to Cefmenoxime, Ceftriaxone, and Other Antimicrobial Compounds

1 reference

12 December 2020

Ceftriaxone: In vitro activity against 410 bacterial isolates compared with cefotaxime

1 reference

12 December 2020

Ro 13-9904: Affinity for penicillin binding proteins and effect on cell wall synthesis

1 reference

12 December 2020

In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases

1 reference

12 December 2020

A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic

1 reference

12 December 2020

Single-dose ceftriaxone pharmacokinetics in pediatric patients with central nervous system infections

1 reference

12 December 2020

Ceftriaxone in the treatment of ordinary and penicillinase-producing strains of Neisseria gonorrhoeae

1 reference

12 December 2020

Ceftriaxone Therapy in Pediatric Patients

1 reference

12 December 2020

Treatment of complicated urinary tract infections with the long acting cephalosporin, ceftriaxone

1 reference

12 December 2020

Efficacy of ceftriaxone in treatment of serious childhood infections

1 reference

12 December 2020

A study of the relationship between dose and pharmacokinetics of ceftriaxone

1 reference

12 December 2020

Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis

1 reference

12 December 2020

The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics

1 reference

12 December 2020

Human pharmacology of ceftriaxone (author's transl)

1 reference

12 December 2020

In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins

1 reference

12 December 2020

The susceptibility of Yersinia to eleven antimicrobials

1 reference

12 December 2020

Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies

1 reference

12 December 2020

Effects of Moxalactam on Blood Coagulation and Platelet function

1 reference

12 December 2020

Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection

1 reference

12 December 2020

[Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams]

1 reference

12 December 2020

Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins

1 reference

12 December 2020

Pharmacologic basis for antimicrobial therapy of neonatal meningitis

1 reference

12 December 2020

In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro and in vivo synergy between ceftriaxone and aminoglycosides againstPseudomonas aeruginosa

1 reference

12 December 2020

The immunosuppressive effect of cephalosporins and cephalosporin-gentamicin combinations.

1 reference

12 December 2020

Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults

1 reference

12 December 2020

In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin

1 reference

12 December 2020

Third-generation beta-lactam antibiotics for treatment of orthopedic infections

1 reference

12 December 2020

Activities of New Beta-Lactam Antibiotics Against Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis

1 reference

12 December 2020

Activity of a new cephalosporin antibiotic, Ro 13-9904 against dense populations of selected enterobacteria

1 reference

12 December 2020

Comparison of the β-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa

1 reference

12 December 2020

The in-vitro activity of ceftazidime compared with that of other cephalosporins.

1 reference

12 December 2020

Ceftriaxone therapy of group B streptococcal bacteraemia and meningitis in infant rats

1 reference

12 December 2020

Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections

1 reference

12 December 2020

Comparison of the activities of ceftriaxone and penicillin G against experimentally induced syphilis in rabbits

1 reference

12 December 2020

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

1 reference

12 December 2020

In-vitro and in- vivo efficacy of ceftriaxone, moxalactam, and chloramphenicol against Haemophilus influenzae type b

1 reference

12 December 2020

The susceptibility of Neisseria gonorrhoeae isolated in Singapore to ceftriaxone, cefotaxime, gentamicin and cotrimoxazole

1 reference

12 December 2020

Susceptibility of Nocardia asteroides to 46 antibiotics, including 22 beta-lactams

1 reference

12 December 2020

Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis

1 reference

12 December 2020

Current status of Pseudomonas infections and antibiotics.

1 reference

12 December 2020

Diffusion of ceftriaxone (Ro 13-9004/001) in the cerebrospinal fluid. Comparison with other beta-lactam antibiotics in dogs with healthy meninges and in dogs with experimental meningitis

1 reference

12 December 2020

The new beta-lactamase-stable cephalosporins

1 reference

12 December 2020

Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings

1 reference

12 December 2020

Beta-lactam antibiotic susceptibility of bacteria responsible for neonatal meningitis

1 reference

12 December 2020

Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis

1 reference

12 December 2020

Properties of Ro 13-99041 as a substrate and inhibitor of beta-lactamases

1 reference

12 December 2020

Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.

1 reference

12 December 2020

Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative

1 reference

12 December 2020

Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli

1 reference

12 December 2020

Ceftriaxone: renal and biliary excretion and effect on the colon microflora

1 reference

12 December 2020

Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin

1 reference

12 December 2020

In vitro activities of new beta-lactam antibiotics against Acinetobacter spp.

1 reference

12 December 2020

Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children

1 reference

12 December 2020

Single-dose ceftriaxone kinetics in functionally anephric patients

1 reference

12 December 2020

Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study

1 reference

12 December 2020

Comparative synergistic activity of ceftriaxone-piperacillin versus ceftriaxone-netilmicin

1 reference

12 December 2020

Clinical study of ceftriaxone (author's transl)

1 reference

12 December 2020

Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose

1 reference

12 December 2020

Antibiotic prophylaxis for genitourinary surgery in community hospitals

1 reference

12 December 2020

Epidemiology of gentamicin-resistant, gram-negative bacillary colonization in a spinal cord injury unit

1 reference

12 December 2020

In vitro susceptibility and cross-resistance of South African isolates of Neisseria gonorrhoeae to 14 antimicrobial agents

1 reference

12 December 2020

Comparative in vitro activity of ceftriaxone against anaerobic bacteria

1 reference

12 December 2020

Unusual Mode of Inhibition of Citrobacter freundii β-Lactamases by Ceftriaxone

1 reference

12 December 2020

Ceftriaxone, a new parenteral cephalosporin, in the treatment of urinary tract infections

1 reference

12 December 2020

Concentrations of ceftriaxone in serum and gynecological tissues

1 reference

12 December 2020

The in-vitro activity of ceftazidime against clinically important pathogens.

1 reference

12 December 2020

Comparative in vitro study of SQ26,776.

1 reference

12 December 2020

Comparative in-vitro activity of selected new beta-lactam antimicrobials against Neisseria gonorrhoeae

1 reference

12 December 2020

In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin

1 reference

12 December 2020

The antimicrobial susceptibility of anaerobic bacteria in a London teaching hospital.

1 reference

12 December 2020

Cephalosporin resistance in strains of Klebsiella oxytoca isolated during antibiotic therapy

1 reference

12 December 2020

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing

1 reference

12 December 2020

Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis

1 reference

12 December 2020

In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents

1 reference

12 December 2020

Pharmacokinetics of ceftriaxone in humans

1 reference

12 December 2020

In vitro susceptibilities of Aeromonas hydrophila against new antibiotics

1 reference

12 December 2020

Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children

1 reference

12 December 2020

Cephalosporin-resistance in the Bacteroides fragilis group and the effect of clavulanic acid

1 reference

12 December 2020

One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin. A dose-range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order

1 reference

12 December 2020

Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases

1 reference

12 December 2020

Efficacy of ceftriaxone in serious bacterial infections

1 reference

12 December 2020

Antibacterial properties of Ro 13-99041, a long-acting new cephalosporin

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin

1 reference

12 December 2020

Clinical use of the new beta-lactam antimicrobial drugs. Practical considerations for physicians, microbiology laboratories, pharmacists, and formulary committees

1 reference

12 December 2020

Susceptibility of group B streptococci to 16 beta-lactam antibiotics, including new penicillin and cephalosporin derivatives

1 reference

12 December 2020

In-vitro studies with ceftazidime

1 reference

12 December 2020

In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp

1 reference

12 December 2020

Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

1 reference

12 December 2020

Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism

1 reference

12 December 2020

Determination of ceftriaxone, a novel cephalosporin, in plasma, urine and saliva by high-performance liquid chromatography on an NH2 bonded-phase column

1 reference

12 December 2020

A model system to demonstrate that beta-lactamase-associated antibiotic trapping could be a potential means of resistance.

1 reference

12 December 2020

In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.

1 reference

12 December 2020

Comparative study of ceftriaxone and spectinomycin for treatment of uncomplicated gonorrhoea in men

1 reference

12 December 2020

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

1 reference

12 December 2020

Comparative in-vitro activity and mode of action of ceftriaxone (Ro 13-9904), a new highly potent cephalosporin

1 reference

12 December 2020

Ceftriaxone: in vitro studies and clinical evaluation

1 reference

12 December 2020

An evaluation of recently developed antibiotics.

1 reference

12 December 2020

In vitro evaluation of Ro 13-9904

1 reference

12 December 2020

Bacteriological comparison of the activities of ceftriaxone, a new long-acting cephalosporin, with those of other new cephalosporins

1 reference

12 December 2020

Ceftriaxone pharmacokinetics in newborn infants

1 reference

12 December 2020

Antimicrobial sensitivity of Neisseria gonorrhoeae. Comparison of penicillinase producing and non-penicillinase producing strains

1 reference

12 December 2020

Comparative activities of 13 beta-lactam antibiotics

1 reference

12 December 2020

Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life

1 reference

12 December 2020

Effect of ceftriaxone on Pseudomonas aeruginosa and Staphylococcus aureus in broth, serum, and in combination with human polymorphonuclear leukocytes.

1 reference

12 December 2020

In vitro activity of Ro 13-9904, cefuroxime, cefoxitin, and ampicillin against Neisseria gonorrhoeae

1 reference

12 December 2020

Resistance to cephalosporins among gentamicin-resistant klebsiellae.

1 reference

12 December 2020

Pharmacokinetics and Bacteriologic Efficacy of Moxalactam, Cefotaxime, Cefoperazone, and Rocephin in Experimental Bacterial Meningitis

1 reference

12 December 2020

Ro 13-9904 and GR 20263, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other beta-lactam antibiotics

1 reference

12 December 2020

Ceftriaxone therapy of serious bacterial infections in adults

1 reference

12 December 2020

In vitro activity of ceftazidime and ceftriaxone

1 reference

12 December 2020

Clinical study of Rocephin, a 3d generation cephalosporin, in various septicaemias

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00003495-198427060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

17 September 2017

1007874029

0 references

1 reference